Inovio Pharmaceuticals (NASDAQ:INO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a sell rating to a hold rating in a research report released on Saturday.

INO has been the topic of a number of other reports. Weiss Ratings cut Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Zacks Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their price target for the company from $1.80 to $3.00 in a report on Thursday. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Thursday. Finally, Piper Sandler restated an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $3.17.

Inovio Pharmaceuticals Stock Up 21.1%

INO stock opened at $1.09 on Friday. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.98. The company has a market cap of $112.71 million, a PE ratio of -1.20 and a beta of 1.52. The business’s 50-day simple moving average is $1.03 and its 200 day simple moving average is $1.30.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. On average, equities research analysts anticipate that Inovio Pharmaceuticals will post -0.72 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Focus Partners Wealth acquired a new position in Inovio Pharmaceuticals during the third quarter worth $33,000. Raymond James Financial Inc. boosted its stake in shares of Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 16,309 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $41,000. Zacks Investment Management acquired a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at $46,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 18,160 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Key Headlines Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: Zacks Research upgraded INO from “Hold” to “Strong Buy,” providing the most significant bullish catalyst in the reports and potentially attracting additional investor interest. Zacks.com
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.73 from a loss of $1.01. The smaller projected loss suggests better-than-previously-expected cost control or operating performance. The firm also improved estimates for the third and fourth quarters of 2026, as well as the first and second quarters of 2027.
• Positive Sentiment: HC Wainwright increased its FY2027 EPS forecast to a loss of $0.21 from $0.24 and raised its Q1 2027 estimate to a loss of $0.15 from $0.18. Its Q2 2027 forecast was improved to a loss of $0.08 from $0.10, indicating expectations for a gradual reduction in losses.
• Neutral Sentiment: Despite the improved forecasts, HC Wainwright maintained a “Neutral” rating on Inovio. Its revised estimates still project losses through FY2027, limiting the strength of the bullish signal.
• Negative Sentiment: HC Wainwright lowered its Q4 2027 EPS forecast to $0.03 from $0.07. Although the estimate remains profitable, the reduction signals weaker expectations for that quarter and partially offsets the broader forecast improvements.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.